European Alliance for
Newborn Screening in Spinal Muscular Atrophy

Opening a new horizon
for children born with spinal muscular atrophy

SMA: Screen at birth, save lives

Identifying children living with SMA through NBS allows for treatment to be started on time, preventing motor neuron death and a life with severe disability or even death.

Learn more about newborn screening for SMA in Europe

Find out more about the status of SMA screening in different countries


Download the latest versions of the SMA NBS Alliance materials

Quick facts about the Alliance and SMA Newborn Screening

Latest News

Newborn screening for SMA in Romania event

The Romanian Association SMACARE in partnership with SMA Europe and the European Alliance for SMA NBS is organizing an event on 25 November in Bucharest, Romania at the Crowne Plaza Hotel Bucharest. The event’s purpose is to discuss newborn screening implementation in Romania at the national level, to understand how NBS is implemented in other […]

Positive developments for SMA newborn screening in Spain and Denmark

On September 15, 2022, the regional government of Galicia, Spain announced they would add three new diseases to the regional screening programme, including SMA, and begin screening for SMA by the end of 2022. Galicia has one of the most comprehensive newborn screening programmes in Spain. There are currently three ongoing pilots for SMA newborn […]

Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in The Netherlands

Read the new article published in August 2022, written in part by SMA NBS Alliance members from the University of Groningen and Novartis Gene Therapies, about the cost-effectiveness of newborn screening for SMA in the Netherlands. The researchers found that NBS for early identification and treatment of SMA versus later symptomatic treatment after clinical diagnosis […]

The European Alliance for Newborn Screening in Spinal Muscular Atrophy demands that by 2025, newborn screening programmes in all European countries include a test for spinal muscular atrophy for all newborn children.